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Statement of findings
Acute-phase serum amyloid A (A-SAA) is a major component of the acute-phase response.
A sustained acute-phase response in rheumatoid arthritis (RA) is associated with increased
joint damage. A-SAA mRNA expression was confirmed in all samples obtained from patients
with RA, but not in normal synovium. A-SAA mRNA expression was also demonstrated in
cultured RA synoviocytes. A-SAA protein was identified in the supernatants of primary
synoviocyte cultures, and its expression colocalized with sites of macrophage accumulation
and with some vascular endothelial cells. It is concluded that A-SAA is produced by inflamed
RA synovial tissue. The known association between the acute-phase response and
progressive joint damage may be the direct result of synovial A-SAA-induced effects on
cartilage degradation.
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A-SAA = acute-phase serum amyloid A; GAPDH = glyceraldehyde-3-phosphate dehydrogenase; PCR = polymerase chain reaction; RA = rheuma-
toid arthritis; RT = reverse transcription; SAA = serum amyloid A.
Introduction: Serum amyloid A (SAA) is the circulating
precursor of amyloid A protein, the fibrillar component of
amyloid deposits. In humans, four SAA genes have been
described. Two genes (SAA1 and SAA2) encode A-SAA and
are coordinately induced in response to inflammation. SAA1
and  SAA2 are 95% homologous in both coding and noncoding
regions. SAA3 is a pseudogene. SAA4 encodes constitutive
SAA and is minimally inducible. A-SAA increases dramatically
during acute inflammation and may reach levels that are 1000-
fold greater than normal. A-SAA is mainly synthesized in the
liver, but extrahepatic production has been demonstrated in
many species, including humans. A-SAA mRNA is expressed in
RA synoviocytes and in monocyte/macrophage cell lines such
as THP-1 cells, in endothelial cells and in smooth muscle cells
of atherosclerotic lesions. A-SAA has also been localized to a
wide range of histologically normal tissues, including breast,
stomach, intestine, pancreas, kidney, lung, tonsil, thyroid,
pituitary, placenta, skin and brain.
Aims: To identify the cell types that produce A-SAA mRNA and
protein, and their location in RA synovium.
Materials and methods: Rheumatoid synovial tissue was
obtained from eight patients undergoing arthroscopic biopsy
and at joint replacement surgery. Total RNA was analyzed by
reverse transcription (RT) polymerase chain reaction (PCR) for
A-SAA mRNA. PCR products generated were confirmed by
Southern blot analysis using human A-SAA cDNA. Localization
of A-SAA production was examined by immunohistochemistry
using a rabbit antihuman A-SAA polyclonal antibody. Primary
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RA synoviocytes were cultured to examine endogenous A-SAA
mRNA expression and protein production.
Results: A-SAA mRNA expression was detected using RT-
PCR in all eight synovial tissue samples studied. Figure 1
demonstrates RT-PCR products generated using synovial
tissue from three representative RA patients. Analysis of RA
synovial tissue revealed differences in A-SAA mRNA levels
between individual RA patients.
In order to identify the cells that expressed A-SAA mRNA in RA
synovial tissue, we analyzed primary human synoviocytes
(n=2). RT-PCR analysis revealed A-SAA mRNA expression in
primary RA synoviocytes (n=2; Fig. 2). The endogenous A-
SAA mRNA levels detected in individual primary RA
synoviocytes varied between patients. These findings are
consistent with A-SAA expression in RA synovial tissue (Fig. 1).
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) levels
were relatively similar in the RA synoviocytes examined (Fig. 2).
A-SAA protein in the supernatants of primary synoviocyte
cultures from four RA patients was measured using ELISA. Mean
values of a control and four RA samples were 77.85, 162.5,
249.8, 321.5 and 339.04mg/l A-SAA, respectively, confirming
the production of A-SAA protein by the primary RA synoviocytes.
Immunohistochemical analysis was performed to localize sites
of A-SAA production in RA synovial tissue. Positive staining
was present in both the lining and sublining layers of all eight
RA tissues examined (Fig. 3a). Staining was intense and most
prominent in the cells closest to the surface of the synovial
lining layer. Positively stained cells were evident in the
perivascular areas of the sublining layer. In serial sections
stained with anti-CD68 monoclonal antibody, positive staining
of macrophages appeared to colocalize with A-SAA-positive
cells (Fig. 3b). Immunohistochemical studies of cultured
primary RA synoviocytes confirmed specific cytoplasmic A-
SAA expression in these cells. The specificity of the staining
was confirmed by the absence of staining found on serial
sections and synoviocyte cells treated with IgG (Fig. 3c).
Discussion: This study demonstrates that A-SAA mRNA is
expressed in several cell populations infiltrating RA synovial
tissue. A-SAA mRNA expression was observed in all eight
unseparated RA tissue samples studied. A-SAA mRNA
expression and protein production was demonstrated in
primary cultures of purified RA synoviocytes. Using
immunohistochemical techniques, A-SAA protein appeared to
colocalize with both lining layer and sublining layer
synoviocytes, macrophages and some endothelial cells. The
detection of A-SAA protein in culture media supernatants
harvested from unstimulated synoviocytes confirms
endogenous A-SAA production, and is consistent with A-SAA
mRNA expression and translation by the same cells. Moreover,
the demonstration of A-SAA protein in RA synovial tissue, RA
cultured synoviocytes, macrophages and endothelial cells is
consistent with previous studies that demonstrated A-SAA
production by a variety of human cell populations.
The RA synovial lining layer is composed of activated
macrophages and fibroblast-like synoviocytes. The macro-
phage is the predominant cell type and it has been shown to
accumulate preferentially in the surface of the lining layer and in
the perivascular areas of the sublining layer. Nevertheless, our
observations strongly suggest that A-SAA is produced not only
by synoviocytes, but also by synovial tissue macrophage
populations. Local A-SAA protein production by vascular
endothelial cells was detected in some, but not all, of the
tissues examined. The reason for the variability in vascular A-
SAA staining is unknown, but may be due to differences in
endothelial cell activation, events related to angiogenesis or the
intensity of local inflammation.
The value of measuring serum A-SAA levels as a reliable
surrogate marker of inflammation has been demonstrated for
several diseases including RA, juvenile chronic arthritis,
psoriatic arthropathy, ankylosing spondylitis, Behçet’s
disease,  reactive arthritis and Crohn’s disease. It has been
suggested that serum A-SAA levels may represent the most
sensitive measurement of the acute-phase reaction. In RA, A-
SAA levels provide the strongest correlations with clinical
Figure 1
Detection of A-SAA mRNA expression in inflamed human synovial
tissue by RT-PCR. Analysis of total RNA from rheumatoid synovium
(n=3, lanes 1–3) was performed using primers for human A-SAA and
GAPDH. The 500 bp molecular weight marker (MW) is highlighted.
Figure 2
Detection of A-SAA mRNA expression in primary human synoviocytes.
RT-PCR analysis was performed using total RNA from individual
rheumatoid primary synoviocytes with primers to human A-SAA and
GAPDH (lanes 1, 2). The 500 bp molecular weight marker (MW) is
highlighted.Arthritis Research    Vol 2 No 2 O’Hara et al
Introduction
SAA is the circulating precursor of amyloid A protein, the
fibrillar component of amyloid deposits [1,2]. Four human
SAA genes have been described. Two genes (SAA1 and
SAA2) encode A-SAA and are coordinately induced in
response to inflammation. SAA1 and SAA2 are 95%
homologous in both coding and noncoding regions. SAA3
is a pseudogene. SAA4 encodes constitutive SAA and is
minimally inducible. A-SAA increases dramatically during
acute inflammation and may reach levels that are 1000-
fold greater than normal [3,4]. A-SAA is mainly synthe-
sized in the liver [5], but extrahepatic production has been
demonstrated in many species, including in humans. A-
SAA mRNA is expressed in RA synoviocytes [6] and in
monocyte/macrophage cell lines such as THP-1 cells
(Human monocyte cell line American Type Culture Collec-
tion Tumor Immunology bank 17 – ATCC TIB) [7], in
endothelial cells and smooth muscle cells of atheroscle-
rotic lesions [8]. A-SAA has also been localized to a wide
range of histologically normal tissues, including breast,
stomach, intestine, pancreas, kidney, lung, tonsil, thyroid,
pituitary, placenta, skin and brain [9].
Materials and methods
Patients
Synovial membrane samples were obtained following
informed consent from patients with RA at arthroscopic
biopsy (n=7) or joint replacement surgery (n=1). RA was
diagnosed according to the criteria of the American
College of Rheumatology [10]. Histologically normal syn-
ovium (n=1) was obtained from the knee joint of a patient
undergoing lower limb amputation.
Isolation and culture of synovial cells
Synovial cells were obtained by enzymatic digestion of
synovial membrane with 1mg/ml collagenase type I (Wor-
thington Biochemical, Freehold, NJ, USA) in RPMI (Gibco-
BRL, Paisley, UK) for 4h at 37°C in 5% carbon dioxide.
Dissociated cells were plated in RPMI supplemented with
10% foetal calf serum (GibcoBRL), 10ml of 1mmol/l
HEPES (GibcoBRL), penicillin (100units/ml), strepto-
mycin (100units/ml) and fungizone (0.25mg/ml). The cells
were grown to confluency (approximately 10 days) at
37°C in a 5% carbon dioxide atmosphere, then harvested
with trypsin and passaged. Synoviocytes were found to be
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measurements of disease activity, and changes in serum levels
best reflect the clinical course.
A number of biologic activities have been described for A-SAA,
including several that are relevant to the understanding of
inflammatory and tissue-degrading mechanisms in human
arthritis. A-SAA induces migration, adhesion and tissue
infiltration of circulating monocytes and polymorphonuclear
leukocytes. In addition, human A-SAA can induce interleukin-1b,
interleukin-1 receptor antagonist and soluble type II tumour
necrosis factor receptor production by a monocyte cell line.
Moreover, A-SAA can stimulate the production of cartilage-
degrading proteases by both human and rabbit synoviocytes.
The effects of A-SAA on protease production are interesting,
because in RA a sustained acute-phase reaction has been
strongly associated with progressive joint damage. The known
association between the acute-phase response and progressive
joint damage may be the direct result of synovial A-SAA-induced
effects on cartilage degradation.
Conclusion: In contrast to noninflamed synovium, A-SAA
mRNA expression was identified in all RA tissues examined. A-
SAA appeared to be produced by synovial tissue synoviocytes,
macrophages and endothelial cells. The observation of A-SAA
mRNA expression in cultured RA synoviocytes and human RA
synovial tissue confirms and extends recently published findings
that demonstrated A-SAA mRNA expression in stimulated RA
synoviocytes, but not in unstimulated RA synoviocytes.
Figure 3
Immunohistological analysis of RA synovial membrane. Serial tissue sections were stained with (a) antibody to A-SAA, (b) anti-CD68 and (c) IgG.
A-SAA-positive cells are seen in the surface of the lining layer and in the perivascular areas. Some vascular endothelial cells are weakly positive (a).
CD68-positive cells are seen throughout the lining layer and in the perivascular areas of the sublining layer. Vascular endothelial cells are negative
(b). No staining was observed in the control sections (c).
(a) (b) (c)http://arthritis-research.com/content/2/2/142
morphologically homogenous fibroblast-like cells and were
used between the third and seventh passage. To confirm
synoviocyte cultures were not contaminated by mono-
cytes, staining for the monocyte marker CD14 was carried
out. Cells were placed in serum-free medium 24h before
total RNA extraction.
Reverse transcription-polymerase chain reaction
Total RNA, isolated from freshly obtained synovial biopsies
or cultured primary synoviocytes, was converted by RT into
cDNA. For each total RNA sample, the following materials
were used for RT at 42°C for 50 min: 1mg total RNA and
200units SuperscriptII (GibcoBRL); RT buffer as supplied;
100mmol/l dithiothreitol, 40units RNasin Ribonucleic
Inhibitor (Promega, Madison, WI, USA); 1.25mmol/l each of
dATP, dCTP, dGTP and dTTP; and 500ng of oligo dTs.
PCR was performed with the following materials: 2.0ml
cDNA; 1.25mmol/l of each of dATP, dCTP, dGTP and
dTTP; 2.5units AmpliTaq (Perkin Elmer, Brachburg, NJ,
USA); 2.5mmol/l MgCl2 (GAPDH) and 2.0mmol/l MgCl2
(A-SAA); 2.5ml 10  ×PCRII buffer (Perkin Elmer) and
20ng of each specific PCR primer pair in a 25ml total
volume. Specific primers for human A-SAA were used to
amplify a 335 base-pair (bp) A-SAA product: sense primer
(5¢-AAG CTT CTT TCC GTT CCT TGG-3¢) and antisense
primer (5¢-GAG AGC AGA GTG AAG AGG AAG C-3¢).
The A-SAA primers used span an intron. Thus, the PCR
generates an unequivocally RNA-derived band, based on
its size. GAPDH primers were designed to generate a 635-
bp product: sense primer (5¢-CCA CCC ATG GCA AAT
TCC ATG GCA-3¢) and antisense primer (5¢-TCT AGA
CGG CAG GTC AGG TCC ACC-3¢). After preincubation
(94°C, 10 min) each PCR sample underwent a 35-cycle
amplification regimen of denaturation (94°C, 1 min), primer
annealing (60–56°C, 1 min) and extension (72°C, 1 min),
with a final extension (72°C, 10 min) in a thermal cycler (MJ
Research, Inc, Cambridge, MA, USA).
Northern blot analysis
Total RNA was isolated (RNeasy, Qiagen, Crawley, UK) from
cultured primary synoviocytes and quantified by ultraviolet
absorption. Of total RNA, 10mg was electrophoresed on a
standard northern gel and transferred onto a nylon mem-
brane (BioRad, Richmond, CA, USA). The human A-SAA
cDNA [11] was radiolabelled to a high specific activity using
[a-32P] dCTP and a random primer labelling system
(Promega). All membranes were probed under high strin-
gency conditions. Blots were exposed to film at –80°C using
intensifying screens and autoradiographic intensity was
quantified using an imaging densitometer.
Southern blot analysis
PCR products generated were run on a 2% agarose gel
and transferred onto a nylon membrane (BioRad) using
standard procedures. Human A-SAA and GAPDH cDNA
probes were radiolabelled to a high specific activity using
[a-32P] dCTP and a random labelling system (Promega).
All membranes were probed under high stringency condi-
tions. Blots were exposed to film at –80°C using intensify-
ing screens.
Measurement of acute-phase serum amyloid A by ELISA
A-SAA protein levels were measured using a sandwich
enzyme immunoassay (Biotrin International, Dublin,
Ireland). Supernatants derived from primary RA synovio-
cyte cultures were harvested. Samples were added to a
microtitre plate, which was precoated with IgG (anti-A-
SAA) and incubated for 1 h. The microtitre plate was
washed and IgG (anti-A-SAA)-horseradish peroxidase
conjugate added. After 1 h incubation and plate washing,
substrate was added. The absorbance was measured at
450nm, using 650nm as a reference. Colour intensity is
directly proportional to the amount of A-SAA in the
sample. The detection limit of the assay was determined
as 2.25mg/l [11].
Immunohistology
Synovial tissue was placed in the cryopreservative embed-
ding media OCT compound (Tissue Tek, Sakura, Finetek,
Europe BV, Zoeterwoude, The Netherlands) and immedi-
ately frozen in liquid nitrogen. Sections (7mm) were cut on
a microtome (Microm HM 505N, GmbH 69190 Walldorf,
Germany), placed on glass slides coated with 2% 3-amino-
propyl-triethoxy-silane (Sigma-Aldrich Ireland Ltd, Dublin,
Ireland) in acetone and dried overnight at room tempera-
ture. Isolated RA synoviocytes were trypsinized and placed
into a six-well plate with apyrogenic cell culture coverslips.
Once grown to confluency, the medium was removed and
the cells were treated with methanol for 15 min. Synovio-
cytes were stained essentially as described for the tissue
sections. Tissue sections were allowed to reach room tem-
perature, fixed in acetone, air-dried and incubated for 1 h at
room temperature with blocking serum (Vectastain Rabbit
Elite Kit, Vector Laboratories Ltd, Peterborough, UK). The
slides were incubated with avidin for 15 min, rinsed and
then incubated with biotin for 15 min. The primary poly-
clonal antibody for A-SAA (1:1200–1:1600; rabbit antihu-
man) was incubated for 1 h at room temperature.
Secondary antibodies (antirabbit and antimouse; Vecta-
stain) were prepared and added to the relevant sections
and incubated for 30 min. The secondary antibody was
washed off and the slides were incubated with
Avidin:Biotinylated enzyme complex solution for 30 min
and incubated for 6 min with 3,3¢-diaminobenzidine and
counterstained in haemotoxylin stain for 1 min.
Results
Acute-phase serum amyloid A mRNA in inflamed human
synovial tissue
RT-PCR analysis was employed to examine peripheral A-
SAA mRNA expression in RA synovial membrane. Endoge-
nous A-SAA mRNA expression was detected in all eightArthritis Research    Vol 2 No 2 O’Hara et al
RA synovial tissue samples studied. Figure 1 demonstrates
RT-PCR products generated using synovial tissue from
three representative RA patients. The specificity of the
cDNAs generated were confirmed by Southern blot analy-
sis using cDNA probes for human A-SAA and GAPDH
(Fig. 4). RA synovial tissue samples examined showed
increased levels of A-SAA mRNA when compared with
normal synovium (Fig. 4; lane 1). Analysis of RA synovial
tissue revealed differences in A-SAA mRNA levels
between individual RA patients. Expression levels of the
house-keeping gene (GAPDH) were similar in all patients.
Acute-phase serum amyloid A mRNA expression in
cultured human synovial cells
In order to identify the cells that express A-SAA mRNA in
RA synovial tissue, we analyzed primary human synovio-
cytes. Northern blot analysis did not detect endogenous A-
SAA mRNA in primary unstimulated RA synoviocytes
(Fig. 5a; lane 1). In contrast, abundant A-SAA mRNA levels
were observed in KB oral epidermal cells [Human Epider-
moid, carcinoma; American Type Culture Collection Certi-
fied cell lines (ATCC CCL) 17] stimulated with interleukin-1
(10ng/ml) and interleukin-6 (10ng/ml) and dexamethasone
(10–6mol/l) for either 24 or 48 h (Fig. 5a; lanes 2 and 3).
RT-PCR analysis revealed A-SAA mRNA expression in
primary RA synoviocytes (n=2; Fig. 2). The sensitivity of the
PCR technique was greatly improved by the utilization of the
ultrapure AmpliTaq gold polymerase (Perkin Elmer). The
endogenous A-SAA mRNA levels detected in individual
primary RA synoviocytes varied between patients. These
findings are consistent with A-SAA expression in RA syn-
ovial tissue (Fig. 1). GAPDH levels were relatively similar in
the RA synoviocyte cells examined (Fig. 2).
Acute-phase serum amyloid A protein in primary
synoviocyte culture supernatants
A-SAA protein was measured by ELISA in the super-
natants of primary synoviocyte cultures from four RA
patients. Supernatants were separated from cell cultures
between the third and seventh passages. Mean values of
control and four RA samples of 77.85, 162.5, 249.8,
321.5 and 339.04mg/l A-SAA, respectively, were
obtained, confirming the production of A-SAA protein by
the primary RA synoviocytes (Fig. 6).
Immunohistochemical localization of acute-phase serum
amyloid A in human synovial tissue and cultured
synoviocytes
Immunohistochemical analysis was performed in order to
localize sites of A-SAA production in RA synovial tissue.
Figure 4
Detection of A-SAA mRNA expression in inflamed human synovial
tissue by RT-PCR. Southern blot analysis of A-SAA and GAPDH
cDNAs generated using total RNA from normal human synovium
(lane 1) and rheumatoid synovium (lane 2).
Figure 5
Northern blot analysis of A-SAA mRNA expression in primary human
synoviocytes. (a) Total RNA isolated from primary synoviocyte cultures
(lane 1), and KB oral epidermal cells stimulated for 24h (lane 2) and
48h (lane 3) with 10ng/ml IL-1, IL-6 and dexamethasone (10–6mol/l).
(b) Agarose gel electrophoresis demonstrating the integrity of total
RNA used for Northern analysis.
Figure 6
Levels of A-SAA detected in culture primary RA synoviocyte
supernatants. Mean values of control and individual RA samples
(RA1–RA4) are indicated. N, number of samples measured per group.Positive A-SAA staining was observed in all eight RA
tissues examined. Positive staining was present in both
the lining and sublining layers of the tissue (Fig. 3a). In the
synovial lining layer, staining was usually intense and most
prominent in the cells closest to the surface. In the sublin-
ing layer positively stained cells were also prominent in the
perivascular areas. In serial sections stained with anti-
CD68 monoclonal antibody, positive staining of some
macrophages appeared to colocalize with A-SAA-positive
cells, particularly those in the lining layer surface and the
perivascular areas (Fig. 3b). In some sections the vascular
endothelium also demonstrated positive A-SAA staining,
but this finding was not consistent. Immunohistochemical
studies of cultured primary RA synoviocytes confirmed
specific cytoplasmic A-SAA expression in these cells
(Fig. 7a). The specificity of the staining was confirmed by
the absence of staining found on serial sections (Fig. 3c)
and synoviocytes (Fig. 7b) treated with IgG.
Discussion
The aim of the present study was to examine synovial A-
SAA production in RA and to identify the cell populations
expressing A-SAA in inflamed tissue. In contrast to non-
inflamed synovium, A-SAA mRNA expression was identi-
fied in all RA tissues examined. A-SAA appeared to be
produced by synovial tissue synoviocytes, macrophages
and endothelial cells.
This study demonstrates that A-SAA mRNA is expressed
in several cell populations infiltrating RA synovial tissue,
but not in normal synovial tissue. First, by employing RT-
PCR, A-SAA mRNA expression was observed in all eight
unseparated RA tissue samples studied. Second, A-SAA
mRNA expression and protein production was demon-
strated in primary cultures of purified RA synoviocytes.
Finally, using immunohistochemical techniques, A-SAA
protein appeared to colocalize with both lining layer and
sublining layer synoviocytes, macrophages and some
endothelial cells. The observation of A-SAA mRNA expres-
sion in cultured RA synoviocytes confirms and extends the
recent findings reported by Kumon et al [6], which demon-
strated A-SAA mRNA expression in stimulated RA syn-
oviocytes, but not in unstimulated RA synoviocytes. The
demonstration of A-SAA production in unstimulated RA
synoviocyte cultures in that study is probably due to the
increased sensitivity of the analytical methods employed.
Additionally, the detection of A-SAA protein in culture
media supernatants harvested from unstimulated synovio-
cytes confirms endogenous A-SAA production and is con-
sistent with A-SAA mRNA expression and translation by
the same cells. Moreover, the demonstration of A-SAA
protein in RA synovial tissue, RA cultured synoviocytes,
macrophages and endothelial cells is consistent with pre-
vious studies [8,9,12] demonstrating A-SAA production
by a variety of human cell populations.
The RA synovial lining layer is composed of activated
macrophages and fibroblast-like synoviocytes [13]. The
macrophage is the predominant cell type and it has been
shown [14] to accumulate preferentially in the surface of
the lining layer. Macrophages also accumulate in the
perivascular areas of the sublining layer [15]. As demon-
strated in the present study, not all lining layer and sublin-
ing layer macrophages appeared to produce A-SAA.
Futher studies of isolated synovial tissue macrophages,
and immunohistological studies employing double-
labelling techniques, will elucidate this observation. Never-
theless, the observations reported in this study strongly
suggest that A-SAA is produced not only by synoviocytes,
but also by synovial tissue macrophage populations. Local
A-SAA protein production by vascular endothelial cells
was detected in some, but not all, of the tissues examined.
http://arthritis-research.com/content/2/2/142
Figure 7
Immunohistochemical analysis of RA synoviocytes. (a) Positive cytoplasmic staining was observed in RA synoviocytes stained with anti-A-SAA
antibody. (b) The specificity of staining was confirmed using synoviocytes stained with isotype-matched IgG.
(a) (b)Arthritis Research    Vol 2 No 2 O’Hara et al
The reason for the variability in vascular A-SAA staining is
unknown, but this variability may be due to differences in
endothelial cell activation, events relating to angiogenesis
or the intensity of local inflammation.
The value of measuring serum A-SAA levels as a reliable
surrogate marker of inflammation has been demonstrated
[1] in several diseases including RA, juvenile chronic
arthritis, psoriatic arthropathy, ankylosing spondylitis,
Behçet’s disease, reactive arthritis and Crohn’s disease. It
has been suggested [16] that serum A-SAA levels may
represent the most sensitive measurement of the acute-
phase reaction. Cunnane et al [16] quantified serum A-
SAA levels in 140 patients with various inflammatory joint
diseases with duration of less than 2 years, and demon-
strated significant correlations with other acute-phase
measurements such as C-reactive protein and the erythro-
cyte sedimentation rate. The magnitude of the A-SAA
response was greatest, and the highest levels occurred in
RA. In RA, A-SAA levels provided the strongest correla-
tions with clinical measurements of disease activity, and
changes in serum levels best reflected the clinical course.
The principal biologic function of A-SAA is not known
[1,2]. A number of biologic activities have been described,
however, including several that are relevant to the under-
standing of inflammatory and tissue degrading mecha-
nisms in human arthritis. A-SAA induces migration,
adhesion and tissue infiltration of circulating monocytes
and polymorphonuclear leucocytes [17]. In addition,
human A-SAA can induce interleukin-1b, interleukin-1
receptor antagonist and soluble type II tumour necrosis
factor receptor production by a monocyte cell line [18].
Moreover, A-SAA can stimulate the production of carti-
lage-degrading proteases by both human and rabbit syn-
oviocytes [19,20]. The effects of A-SAA on protease
production are particularly interesting because, in RA, a
sustained acute-phase reaction has been strongly associ-
ated with progressive joint damage [21]. The known asso-
ciation between the acute-phase response and
progressive joint damage may be the direct result of syn-
ovial A-SAA-induced effects on cartilage degradation.
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